Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, et al. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: results from the Lung Cancer Mutation Consortium. Cancer. 2016;122:766–72. https://doi.org/10.1002/cncr.29812.

Article  CAS  PubMed  Google Scholar 

Schoenmaekers J, Paats MS, Dingemans AC and Hendriks LEL. Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when? Transl Lung Cancer Res. 2020; 9: 2599–2617. 2021/01/26. https://doi.org/10.21037/tlcr-20-459.

Kelly WJ, Shah NJ and Subramaniam DS. Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer. Front Oncol. 2018; 8: 208. 2018/07/19. https://doi.org/10.3389/fonc.2018.00208.

Li W-Y, Zhao T-T, Xu H-M, Wang Z-N, Xu Y-Y, Han Y, et al. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19:145. https://doi.org/10.1186/s12885-019-5331-z.

Article  PubMed  PubMed Central  Google Scholar 

Yang XN, Yan HH, Wang J, Chu XY, Liu ZD, Shen Y, et al. Real-world survival outcomes based on EGFR mutation status in Chinese patients with lung adenocarcinoma after complete resection: results from the ICAN study. JTO Clin Res Rep. 2022; 3: 100257. 2022/01/04. https://doi.org/10.1016/j.jtocrr.2021.100257.

Harada D, Takigawa N. Oligoprogression in non-small cell lung cancer. Cancers. 2021;13:5823.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fujita Y, Kinoshita M, Ozaki T, Takano K, Kunimasa K, Kimura M, et al. The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases. Neurooncol Adv. 2020; 2. https://doi.org/10.1093/noajnl/vdaa064.

Boire A, Brastianos PK, Garzia L, Valiente M. Brain metastasis. Nat Rev Cancer. 2020;20:4–11. https://doi.org/10.1038/s41568-019-0220-y.

Article  CAS  PubMed  Google Scholar 

Ahluwalia MS, Becker K and Levy BP. Epidermal growth factor receptor tyrosine kinase inhibitors for central nervous system metastases from non-small cell lung cancer. Oncologist. 2018; 23: 1199–1209. 2018/04/14. https://doi.org/10.1634/theoncologist.2017-0572.

Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, et al. Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor. Cancer. 2013;119:4325–32. https://doi.org/10.1002/cncr.28364.

Article  CAS  PubMed  Google Scholar 

Passaro A, Gianoncelli L, Stati V and de Marinis F. Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding. Ann Transl Med. 2019;7(Suppl 3):S80.

Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, et al. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019; 125: 892–901. 2018/12/05. https://doi.org/10.1002/cncr.31891.

Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, et al. CNS Efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018; 36: 2702–2709. 2018/07/31. https://doi.org/10.1200/jco.2018.77.9363.

Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21: e18-e28. 2020/01/08. https://doi.org/10.1016/s1470-2045(19)30718-1.

Chang JY and Verma V. Optimize local therapy for oligometastatic and oligoprogressive non-small cell lung cancer to enhance survival. J Natl Compr Cancer Netw. 2022; 20: 531–539. 2022/05/12. https://doi.org/10.6004/jnccn.2021.7117.

Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, et al. Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: a systematic review and meta-analysis. Cancers (Basel). 2022; 14 2022/03/26. https://doi.org/10.3390/cancers14061404.

Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, et al. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Crit Rev Oncol Hematol. 2022; 170: 103596. 2022/01/16. https://doi.org/10.1016/j.critrevonc.2022.103596.

Rizzo A. Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate. Br J Cancer. 2022; 127: 1381–1382. 2022/09/06. https://doi.org/10.1038/s41416-022-01929-w.

Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, et al. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother. 2023; 72: 1365–1379. 2023/01/13. https://doi.org/10.1007/s00262-022-03349-4.

Merino Lara T, Helou J, Poon I, Sahgal A, Chung HT, Chu W, et al. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: delaying the need to start or change systemic therapy? Lung Cancer. 2018;124:219–26. https://doi.org/10.1016/j.lungcan.2018.08.005.

Article  PubMed  Google Scholar 

Lim JU. Management of oligometastasis and oligoprogression in patients with epidermal growth factor receptor mutation-positive NSCLC in the era of third-generation tyrosine kinase inhibitors. Clin Lung Cancer. 2021; 22: e786-e792. 2021/04/15. https://doi.org/10.1016/j.cllc.2021.03.004.

Tsai CJ, Yang JT, Guttmann DM, Shaverdian N, Shepherd AF, Eng J, et al. Consolidative use of radiotherapy to block (CURB) oligoprogression ― interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast. Int J Radiat Oncol Biol Phys. 2021; 111: 1325–1326. https://doi.org/10.1016/j.ijrobp.2021.09.014.

Tsui DCC, Camidge DR and Rusthoven CG. Managing central nervous system spread of lung cancer: the state of the art. J Clin Oncol. 2022; 40: 642–660. 2022/01/06. https://doi.org/10.1200/jco.21.01715.

Xu Q, Liu H, Meng S, Jiang T, Li X, Liang S, et al. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. J Cancer. 2019; 10: 522–529. 2019/02/06. https://doi.org/10.7150/jca.26494.

Chan OSH, Lee VHF, Mok TSK, Mo F, Chang ATY and Yeung RMW. The role of radiotherapy in epidermal growth factor receptor mutation-positive patients with oligoprogression: a matched-cohort analysis. Clin Oncol (R Coll Radiol). 2017; 29: 568–575. 2017/05/14. https://doi.org/10.1016/j.clon.2017.04.035.

Nguyen KT, Sakthivel G, Milano MT, Qiu H, Singh DP. Oligoprogression in non-small cell lung cancer: a narrative review. J Thorac Dis. 2022;14:4998–5011.

Article  PubMed  PubMed Central  Google Scholar 

Patel PH, Palma D, McDonald F, Tree AC. The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? Clin Oncol. 2019;31:824–33. https://doi.org/10.1016/j.clon.2019.05.015.

Article  CAS  Google Scholar 

Joosten PJM, de Langen AJ, van der Noort V, Monkhorst K, Klomp HM, Veenhof AAFA, et al. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer. Lung Cancer. 2021;161:141–51. https://doi.org/10.1016/j.lungcan.2021.09.019.

Article  CAS  PubMed  Google Scholar 

Willmann J, Vlaskou Badra E, Adilovic S, Ahmadsei M, Christ SM, van Timmeren JE, et al. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: a retrospective single center study. Radiother Oncol. 2022; 168: 256–264. 2022/02/02. https://doi.org/10.1016/j.radonc.2022.01.019.

Baker S, Mou B, Jiang W, Liu M, Bergman AM, Schellenberg D, et al. Validation of the prognostic utility of ESTRO/EORTC oligometastatic disease classification: a secondary analysis from the population-based phase II SABR-5 trial. Int J Radiat Oncol Biol Phys. 2022; 114: 849–855. 2022/10/28. https://doi.org/10.1016/j.ijrobp.2022.08.026.

Chen HJ, Tu CY, Hsia TC, Fang HY, Chen CH, Chen SC, et al. Prognostic significance of oligometastatic disease classification by the ESTRO/EORTC of cancer for patients with lung cancer treated with definitive radical radiotherapy. Anticancer Res. 2020; 40: 5895–5899. 2020/09/30. https://doi.org/10.21873/anticanres.14609.

Qiu B, Liang Y, Li Q, Liu G, Wang F, Chen Z, et al. Local therapy for oligoprogressive disease in patients with advanced stage non-small-cell lung cancer harboring epidermal growth factor receptor mutation. Clin Lung Cancer. 2017; 18: e369-e373. 2017/05/04. https://doi.org/10.1016/j.cllc.2017.04.002.

Rossi A, Galetta D. Systemic therapy for oligoprogression in patients with metastatic NSCLC harboring activating EGFR mutations. Cancers. 2022;14:832.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aldea M, Hendriks L, Mezquita L, Jovelet C, Planchard D, Auclin E, et al. Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression. J Thorac Oncol. 2020;15:383–91. https://doi.org/10.1016/j.jtho.2019.11.024.

Article  CAS  PubMed  Google Scholar 

Zhao Y, Li S, Yang X, Chu L, Wang S, Tong T, et al. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis. Int J Cancer. 2022; 150: 1318–1328. 2021/12/17. https://doi.org/10.1002/ijc.33904.

Eide IJZ, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, et al. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). Lung Cancer. 2020; 143: 27–35. 2020/03/23. https://doi.org/10.1016/j.lungcan.2020.03.009.

Tonse R, Rubens M, Appel H, Tom MC, Hall MD, Odia Y, et al. Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance. Discover Oncology. 2021;12:48. https://doi.org/10.1007/s12672-021-00445-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alvarez-Breckenridge C, Remon J, Piña Y, Nieblas-Bedolla E, Forsyth P, Hendriks L, et al. Emerging systemic treatment perspectives on brain metastases: moving toward a better outlook for patients. Am Soc Clin Oncol Educ Book. 2022: 147–165. https://doi.org/10.1200/EDBK_352320.

Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, Aquilanti E, et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020;52:371–7. https://doi.org/10.1038/s41588-020-0592-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, et al. Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. Curr Oncol. 2019; 26: e81-e93. 2019/03/12. https://doi.org/10.3747/co.26.4116.

Baydoun A, Lee VL, Biswas T. Oligometastatic non-small cell lung cancer: a practical review of prospective trials. Cancers. 2022;14:5339.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson M, Garassino MC, Mok T and Mitsudomi T. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies. Lung Cancer. 2022; 170: 41–51. 2022/06/18. https://doi.org/10.1016/j.lungcan.2022.05.011.